Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Salla Ruosaari is active.

Publication


Featured researches published by Salla Ruosaari.


Clinical Cancer Research | 2009

Genomic Profiles Associated with Early Micrometastasis in Lung Cancer: Relevance of 4q Deletion

Michaela Wrage; Salla Ruosaari; Paul P. Eijk; Jussuf T. Kaifi; Jaakko Hollmén; Emre F. Yekebas; Jakob R. Izbicki; Ruud H. Brakenhoff; Thomas Streichert; Sabine Riethdorf; Markus Glatzel; Bauke Ylstra; Klaus Pantel; Harriet Wikman

Purpose: Bone marrow is a common homing organ for early disseminated tumor cells (DTC) and their presence can predict the subsequent occurrence of overt metastasis and survival in lung cancer. It is still unclear whether the shedding of DTC from the primary tumor is a random process or a selective release driven by a specific genomic pattern. Experimental Design: DTCs were identified in bone marrow from lung cancer patients by an immunocytochemical cytokeratin assay. Genomic aberrations and expression profiles of the respective primary tumors were assessed by microarrays and fluorescence in situ hybridization analyses. The most significant results were validated on an independent set of primary lung tumors and brain metastases. Results: Combination of DNA copy number profiles (array comparative genomic hybridization) with gene expression profiles identified five chromosomal regions differentiating bone marrow-negative from bone marrow-positive patients (4q12-q32, 10p12-p11, 10q21-q22, 17q21, and 20q11-q13). Copy number changes of 4q12-q32 were the most prominent finding, containing the highest number of differentially expressed genes irrespective of chromosomal size (P = 0.018). Fluorescence in situ hybridization analyses on further primary lung tumor samples confirmed the association between loss of 4q and bone marrow-positive status. In bone marrow-positive patients, 4q was frequently lost (37% versus 7%), whereas gains could be commonly found among bone marrow-negative patients (7% versus 17%). The same loss was also found to be common in brain metastases from both small and non-small cell lung cancer patients (39%). Conclusions: Thus, our data indicate, for the first time, that early hematogenous dissemination of tumor cells might be driven by a specific pattern of genomic changes.


Cancer Research | 2008

Epigenetic signatures of familial cancer are characteristic of tumor type and family category.

Emmi I. Joensuu; Wael M. Abdel-Rahman; Miina Ollikainen; Salla Ruosaari; Sakari Knuutila; Päivi Peltomäki

Tumor suppressor genes (TSG) may be inactivated by methylation of critical CpG sites in their promoter regions, providing targets for early detection and prevention. Although sporadic cancers, especially colorectal carcinoma (CRC), have been characterized for epigenetic changes extensively, such information in familial/hereditary cancer is limited. We studied 108 CRCs and 63 endometrial carcinomas (EC) occurring as part of hereditary nonpolyposis CRC, as separate familial site-specific entities or sporadically, for promoter methylation of 24 TSGs. Eleven genes in CRC and 6 in EC were methylated in at least 15% of tumors and together accounted for 89% and 82% of promoter methylation events in CRC and EC, respectively. Some genes (e.g., CDH13, APC, GSTP1, and TIMP3) showed frequent methylation in both cancers, whereas promoter methylation of ESR1, CHFR, and RARB was typical of CRC and that of RASSF1(A) characterized EC. Among CRCs, sets of genes with methylation characteristic of familial versus sporadic tumors appeared. A TSG methylator phenotype (methylation of at least 5 of 24 genes) occurred in 37% of CRC and 18% of EC (P = 0.013), and the presence versus absence of MLH1 methylation divided the tumors into high versus low methylation groups. In conclusion, inactivation of TSGs by promoter methylation followed patterns characteristic of tumor type (CRC versus EC) and family category and was strongly influenced by MLH1 promoter methylation status in all categories. Paired normal tissues or blood displayed negligible methylation arguing against a constitutional methylation abnormality in familial cases.


Cancer Research | 2006

Identification of specific gene copy number changes in asbestos-related lung cancer

Penny Nymark; Harriet Wikman; Salla Ruosaari; Jaakko Hollmén; Esa Vanhala; Antti Karjalainen; Sisko Anttila; Sakari Knuutila

Asbestos is a well-known lung cancer-causing mineral fiber. In vitro and in vivo experiments have shown that asbestos can cause chromosomal damage and aberrations. Lung tumors, in general, have several recurrently amplified and deleted chromosomal regions. To investigate whether a distinct chromosomal aberration profile could be detected in the lung tumors of heavily asbestos-exposed patients, we analyzed the copy number profiles of 14 lung tumors from highly asbestos-exposed patients and 14 matched tumors from nonexposed patients using classic comparative genomic hybridization (CGH). A specific profile could lead to identification of the underlying genes that may act as mediators of tumor formation and progression. In addition, array CGH analyses on cDNA microarrays (13,000 clones) were carried out on 20 of the same patients. Classic CGH showed, on average, more aberrations in asbestos-exposed than in nonexposed patients, and an altered region in chromosome 2 seemed to occur more frequently in the asbestos-exposed patients. Array CGH revealed aberrations in 18 regions that were significantly associated with either of the two groups. The most significant regions were 2p21-p16.3, 5q35.3, 9q33.3-q34.11, 9q34.13-q34.3, 11p15.5, 14q11.2, and 19p13.1-p13.3 (P < 0.005). Furthermore, 11 fragile sites coincided with the 18 asbestos-associated regions (P = 0.08), which may imply preferentially caused DNA damage at these sites. Our findings are the first evidence, indicating that asbestos exposure may produce a specific DNA damage profile.


Oncogene | 2007

Gene expression and copy number profiling suggests the importance of allelic imbalance in 19p in asbestos-associated lung cancer

Harriet Wikman; Salla Ruosaari; Penny Nymark; Virinder Kaur Sarhadi; Juha Saharinen; Esa Vanhala; Antti Karjalainen; Jaakko Hollmén; Sakari Knuutila; Sisko Anttila

Asbestos is a pulmonary carcinogen known to give rise to DNA and chromosomal damage, but the exact carcinogenic mechanisms are still largely unknown. In this study, gene expression arrays were performed on lung tumor samples from 14 heavily asbestos-exposed and 14 non-exposed patients matched for other characteristics. Using a two-step statistical analysis, 47 genes were revealed that could differentiate the tumors of asbestos-exposed from those of non-exposed patients. To identify asbestos-associated regions with DNA copy number and expressional changes, the gene expression data were combined with comparative genomic hybridization microarray data. As a result, a combinatory profile of DNA copy number aberrations and expressional changes significantly associated with asbestos exposure was obtained. Asbestos-related areas were detected in 2p21–p16.3, 3p21.31, 5q35.2–q35.3, 16p13.3, 19p13.3–p13.1 and 22q12.3–q13.1. The most prominent of these, 19p13, was further characterized by microsatellite analysis in 62 patients for the differences in allelic imbalance (AI) between the two groups of lung tumors. 79% of the exposed and 45% of the non-exposed patients (P=0.008) were found to be carriers of AI in their lung tumors. In the exposed group, AI in 19p was prevalent regardless of the histological tumor type. In adenocarcinomas, AI in 19p appeared to occur independently of the asbestos exposure.


Carcinogenesis | 2008

Aberrations of chromosome 19 in asbestos-associated lung cancer and in asbestos-induced micronuclei of bronchial epithelial cells in vitro

Salla Ruosaari; Penny Nymark; Mervi Aavikko; Eeva Kettunen; Sakari Knuutila; Jaakko Hollmén; Hannu Norppa; Sisko Anttila

Exposure to asbestos is known to induce lung cancer, and our previous studies have suggested that specific chromosomal regions, such as 19p13, are preferentially aberrant in lung tumours of asbestos-exposed patients. Here, we further examined the association between the 19p region and exposure to asbestos using array comparative genomic hybridization and fluorescence in situ hybridization (FISH) in lung tumours and FISH characterization of asbestos-induced micronuclei (MN) in human bronchial epithelial BEAS 2B cells in vitro. We detected an increased number of 19p losses in the tumours of asbestos-exposed patients in comparison with tumours from non-exposed subjects with similar distribution of tumour histology in both groups (13/33; 39% versus 3/25; 12%, P = 0.04). In BEAS 2B cells, a 48 h exposure to crocidolite asbestos (2.0 microg/cm(2)) was found to induce centromere-negative MN-harbouring chromosomal fragments. Furthermore, an increased frequency of rare MN containing a 19p fragment was observed after the crocidolite treatment in comparison with untreated controls (6/6000 versus 1/10 000, P = 0.01). The results suggest that 19p has significance in asbestos-associated carcinogenesis and that asbestos may be capable of inducing specific chromosome aberrations.


Clinical Cancer Research | 2009

Molecular Alterations at 9q33.1 and Polyploidy in Asbestos-Related Lung Cancer

Penny Nymark; Eeva Kettunen; Mervi Aavikko; Salla Ruosaari; Eeva Kuosma; Esa Vanhala; Kaisa Salmenkivi; Risto Pirinen; Antti Karjalainen; Sakari Knuutila; Harriet Wikman; Sisko Anttila

Purpose: Asbestos causes DNA damage and the fibers, together with tobacco smoke, have a synergistic effect on lung cancer risk. We recently identified 18 chromosomal regions that showed differences in DNA copy number between the lung tumors of asbestos-exposed and nonexposed patients. One of the previously identified asbestos-associated chromosomal regions at 9q was further analyzed for allelic imbalance and DNA copy number alterations (CNA) in the lung tumors of asbestos-exposed and nonexposed patients. In addition, the ploidy level of the tumors was studied. Experimental Design: Allelic imbalance was analyzed at 9q31.3-34.3 with 15 microsatellite markers in 52 lung tumor samples from asbestos-exposed and nonexposed patients. CNA at 9q32-34.3 were characterized by fluorescent in situ hybridization (FISH) with six bacterial artificial chromosome probes in 95 lung tumors. The ploidy level was analyzed in 100 lung tumors with FISH using three to five centromere probes. Results: Allelic imbalance at 9q31.3-q34.3 was found in all asbestos-exposed patient tumors (100%, 17 of 17) compared with 64% (14 of 22) in the nonexposed cases (P = 0.005). The most significant difference was detected at 9q33.1 (P = 0.002). FISH results showed that also CNA were more frequent at 9q33.1 in the three major histologic types of non–small-cell lung tumors of exposed patients, and the association showed a dose-dependent trend (P = 0.03). Furthermore, we detected more frequent polyploidy among the exposed (48%, 28 of 58) than among the nonexposed (29%, 12 of 42) patient tumors (P < 0.05). Conclusions: These results provide a basis for the development of a method to identify asbestos-related lung cancer on a molecular level.


discovery science | 2002

Image Analysis for Detecting Faulty Spots from Microarray Images

Salla Ruosaari; Jaakko Hollmén

Microarrays allow the monitoring of thousands of genes simultaneously. Before a measure of gene activity of an organism is obtained, however, many stages in the error-prone manual and automated process have to be performed. Without quality control, the resulting measures may, instead of being estimates of gene activity, be due to noise or systematic variation. We address the problem of detecting spots of low quality from the microarray images to prevent them to enter the subsequent analysis. We extract features describing spatial characteristics of the spots on the microarray image and train a classifier using a set of labeled spots. We assess the results for classification of individual spots using ROC analysis and for a compound classification using a non-symmetric cost structure for misclassifications.


BMC Medical Genomics | 2008

Pathways affected by asbestos exposure in normal and tumour tissue of lung cancer patients

Salla Ruosaari; Tuija Hienonen-Kempas; Anne Puustinen; Virinder Sarhadi; Jaakko Hollmén; Sakari Knuutila; Juha Saharinen; Harriet Wikman; Sisko Anttila

BackgroundStudies on asbestos-induced tumourigenesis have indicated the role of, e.g., reactive oxygen/nitrogen species, mitochondria, as well as NF-κB and MAPK signalling pathways. The exact molecular mechanisms contributing to asbestos-mediated carcinogenesis are, however, still to be characterized.MethodsIn this study, gene expression data analyses together with gene annotation data from the Gene Ontology (GO) database were utilized to identify pathways that are differentially regulated in lung and tumour tissues between asbestos-exposed and non-exposed lung cancer patients. Differentially regulated pathways were identified from gene expression data from 14 asbestos-exposed and 14 non-exposed lung cancer patients using custom-made software and Iterative Group Analysis (iGA). Western blotting was used to further characterize the findings, specifically to determine the protein levels of UBA1 and UBA7.ResultsDifferences between asbestos-related and non-related lung tumours were detected in pathways associated with, e.g., ion transport, NF-κB signalling, DNA repair, as well as spliceosome and nucleosome complexes. A notable fraction of the pathways down-regulated in both normal and tumour tissue of the asbestos-exposed patients were related to protein ubiquitination, a versatile process regulating, for instance, DNA repair, cell cycle, and apoptosis, and thus being also a significant contributor of carcinogenesis. Even though UBA1 or UBA7, the early enzymes involved in protein ubiquitination and ubiquitin-like regulation of target proteins, did not underlie the exposure-related deregulation of ubiquitination, a difference was detected in the UBA1 and UBA7 levels between squamous cell carcinomas and respective normal lung tissue (p = 0.02 and p = 0.01) without regard to exposure status.ConclusionOur results indicate alterations in protein ubiquitination related both to cancer type and asbestos. We present for the first time pathway analysis results on asbestos-associated lung cancer, providing important insight into the most relevant targets for future research.


Journal of Thoracic Oncology | 2007

P2-015: Frequent DNA copy number gains in 2p in lung cancer

Eeva Kettunen; Mervi Aavikko; Penny Nymark; Salla Ruosaari; Harriet Wikman; Eeva Kuosma; Sisko Anttila

tion was achieved less often in women than in men (p=0.004). In men,the expression of EGFR,VEGF,p53,P21,CerbB2 of NSCLC was 47.1%,36.0%, 36.8%,49.3% and 30.1% respectively. In women, the expression of EGFR, VEGF, p53,P21, CerbB2 of NSCLC was 42.4%,29.6%,21.6%,26.4% and 48.8% respectively. Female gender significantly increased the risk of high expression of CerbB2, RR: 2.208, 95%CI: 1.330-3.667, p=0.002, and decreased the risk of high expression of P21, RR: 0.372, 95%CI: 0.159--0.870 p=0.023. The high expression of EGFR and VEGF may indicated the poor prognosis. The expression of p53 was significantly related to smoking. Conclusions: Women with lung cancer were more peripheral type and smoked less intensively but had more passive smoking. Over-representation of adenocarcinoma and smaller lesions was observed in the women. Women with lung cancer had a better lung function and expression of CerbB2 in NSCLC related to women but expression of P21 has been verified associated with smoking correlated with men. Our study suggested the interaction between environmental and genetic factors is important.


BMC Genomics | 2007

Gene expression profiles in asbestos-exposed epithelial and mesothelial lung cell lines

Penny Nymark; Pamela Lindholm; Mikko Korpela; Leo Lahti; Salla Ruosaari; Samuel Kaski; Jaakko Hollmén; Sisko Anttila; Vuokko L. Kinnula; Sakari Knuutila

Collaboration


Dive into the Salla Ruosaari's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Juha Saharinen

Tampere University of Technology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kaisa Salmenkivi

Helsinki University Central Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Pamela Lindholm

Helsinki University Central Hospital

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge